GrowthWorks Canadian Fund
Rosetta Capital completed a secondary transaction involving debt and equity to secure a portfolio of US and Canadian life sciences assets from GrowthWorks, a Canadian fund manager.
Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience.
Supporting portfolio companies for the next growth phase
Rosetta Capital supported the portfolio companies acquired in the transaction through the growth phase and made several follow-on investments.
Rosetta partners joined the boards of acquired portfolio companies and were actively involved in strategic decision making, leading to multiple exits.
The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company’s holdings in delivering sustainable value and positive long-term shareholder returns.”
Tim Creed and Ben Wicks
Portfolio Managers at Schroder UK Public Private Trust plc